References & Citations
Quantitative Biology > Tissues and Organs
Title: CAR T cell therapy in B-cell acute lymphoblastic leukaemia: Insights from mathematical models
(Submitted on 18 Mar 2020 (v1), last revised 27 Aug 2020 (this version, v2))
Abstract: Immunotherapies use components of the patient immune system to selectively target cancer cells. The use of CAR T cells to treat B-cell malignancies --leukaemias and lymphomas-- is one of the most successful examples, with many patients experiencing long-lasting complete responses to this therapy. This treatment works by extracting the patient's T cells and adding them the CAR group, which enables them to recognize and target cells carrying the antigen CD19+, that is expressed in these haematological tumors.
Here we put forward a mathematical model describing the time response of leukaemias to the injection of CAR T-cells. The model accounts for mature and progenitor B-cells, tumor cells, CAR T cells and side effects by incorporating the main biological processes involved. The model explains the early post-injection dynamics of the different compartments and the fact that the number of CAR T cells injected does not critically affect the treatment outcome. An explicit formula is found that provides the maximum CAR T cell expansion in-vivo and the severity of side effects. Our mathematical model captures other known features of the response to this immunotherapy. It also predicts that CD19+ tumor relapses could be the result of the competition between tumor and CAR T cells analogous to predator-prey dynamics. We discuss this fact on the light of available evidences and the possibility of controlling relapses by early re-challenging of the tumor with stored CAR T cells.
Submission history
From: Victor M. Perez-Garcia [view email][v1] Wed, 18 Mar 2020 21:18:39 GMT (5076kb,D)
[v2] Thu, 27 Aug 2020 17:01:20 GMT (5167kb,D)
Link back to: arXiv, form interface, contact.